While previous studies show that complete CD47 ablation can favor suppression and even complete rejection of IgG-opsonized B16F10 tumors (Andrechak et al., 2022; Dooling et al., 2022; Hayes et al., 2022; Kamber et al., 2021), inter-experimental variation is high, particularly regarding complete tumor rejection and clearance. Here, CD47 is linked to neoplasm.